

NOT FOR PUBLICATION, QUOTATION, OR CITATION

The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields.

The American College of Radiology will periodically define new practice parameters and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice parameters and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each practice parameter and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review and approval. The practice parameters and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized.

ACR–ASNR–SIR–SNIS PRACTICE PARAMETER FOR THE PERFORMANCE OF ENDOVASCULAR EMBOLCTOMY AND REVASCULARIZATION IN ACUTE STROKE

PREAMBLE

This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care¹. For these reasons and those set forth below, the American College of Radiology and our collaborating medical specialty societies caution against the use of these documents in litigation in which the clinical decisions of a practitioner are called into question.

The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the practitioner in light of all the circumstances presented. Thus, an approach that differs from the guidance in this document, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in this document when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of this document. However, a practitioner who employs an approach substantially different from the guidance in this document is advised to document in the patient record information sufficient to explain the approach taken.

The practice of medicine involves not only the science, but also the art of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment.

¹ *Iowa Medical Society and Iowa Society of Anesthesiologists v. Iowa Board of Nursing*, ___ N.W.2d ___ (Iowa 2013) Iowa Supreme Court refuses to find that the *ACR Technical Standard for Management of the Use of Radiation in Fluoroscopic Procedures* (Revised 2008) sets a national standard for who may perform fluoroscopic procedures in light of the standard’s stated purpose that ACR standards are educational tools and not intended to establish a legal standard of care. See also, *Stanley v. McCarver*, 63 P.3d 1076 (Ariz. App. 2003) where in a concurring opinion the Court stated that “published standards or guidelines of specialty medical organizations are useful in determining the duty owed or the standard of care applicable in a given situation” even though ACR standards themselves do not establish the standard of care.

NOT FOR PUBLICATION, QUOTATION, OR CITATION

Therefore, it should be recognized that adherence to the guidance in this document will not assure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of this document is to assist practitioners in achieving this objective.

I. INTRODUCTION

This practice parameter was developed and written with the collaboration of the American College of Radiology (ACR), the American Society of Neuroradiology (ASNR), the Society of Interventional Radiology (SIR), and the Society of NeuroInterventional Surgery (SNIS). This practice parameter will focus on several areas, including: (i) recent advances in endovascular stroke care, (ii) qualifications and responsibilities of the endovascular stroke team, (iii) recommendations regarding equipment and instrumentation, (iv) technical aspects and/or recommendations regarding performance and reporting of the endovascular procedure and peri-procedure care, and (v) recommendations on quality control and performance improvement.

Every year in the United States, an estimated 795,000 people suffer an ischemic stroke. It is estimated that approximately 10%, or nearly 80,000, of these strokes will be caused by an emergent large vessel occlusion (ELVO) affecting the intracranial internal carotid artery, the proximal middle cerebral artery, the intracranial vertebral arteries, or the basilar artery. The effect of this is devastating: ELVO strokes are associated with greater symptoms and worse outcomes, for a disease that, overall, is a leading cause of death and disability, and has been associated with indirect and direct societal costs of up to \$34 billion [1].

The status of endovascular stroke therapy changed significantly in 2015 with the publication of 5 randomized controlled trials that showed a substantial benefit of mechanical thrombectomy in select patients presenting with acute neurological symptoms attributable to a large vessel occlusion within 6 hours from time of onset [2-6]. There are an estimated 24 per 100,000 ELVO strokes per year in the United States. Some regions in the country are performing 10 to 12 endovascular stroke procedures per 100,000 population whereas the national average is at 3 to 6 endovascular stroke interventions per 100,000 people [7]. These estimates suggest a potential for significant growth in the endovascular stroke procedure volume. Endovascular treatment of ELVO acute ischemic stroke (AIS) has evolved rapidly in the last decade. ELVO AIS has been transformed from a nearly hopeless condition to one in which lives and neurological function can be saved. New embolectomy devices, imaging techniques, and systems of care have truly revolutionized the care of the stroke patient. Within the first 6 hours after onset of symptoms, many patients can be treated safely and effectively, with good clinical outcomes being achieved in a significant number of cases. The newest clinical trial results suggest that many patients who awaken with stroke symptoms or are treated between 6 and 24 hours of symptom onset may also benefit provided they have a favorable imaging profile (eg, DAWN or DEFUSE-3 [8]). Of necessity, the practice parameter outlined below will evolve based on new clinical trial results and other lines of evidence.

II. DEFINITIONS

For the purpose of this practice parameter, the following definitions apply:

Alberta Stroke Program Early Computed Tomographic Score (ASPECTS) – a method of measuring early ischemic change, originally described with non-contrast (CT) [9] and subsequently applied to other CT applications and to MRI [10-13], which predicts functional outcome and hemorrhage risk in patients who are candidates for intravenous thrombolysis and thrombectomy.

Class of recommendation – A *Class 1* recommendation represents a strong recommendation or indication, for which there is evidence for and/or general agreement that the procedure or treatment is useful and effective. A *Class 2a* recommendation represents a moderate level of recommendation, in which a course of action is

NOT FOR PUBLICATION, QUOTATION, OR CITATION

46 considered reasonable or may be useful or beneficial. The weight of evidence or opinion is in favor of the
47 procedure or treatment. A *Class 2b* recommendation represents a weaker recommendation, in which a course of
48 action might be reasonable, may be considered, or where the usefulness/effectiveness is considered uncertain or
49 less well established by evidence or opinion. A *Class 3* recommendation represents a course of action for which
50 there is evidence and/or general agreement that the procedure or treatment is not useful/effective, and in some
51 cases may be harmful [14,15].

52
53 CNS infarction – CNS infarction is brain, spinal cord, or retinal cell death attributable to ischemia, based on
54 pathological, imaging, or other objective evidence of cerebral, spinal cord, or retinal focal ischemic injury in a
55 defined vascular distribution; or clinical evidence of cerebral, spinal cord, or retinal focal ischemic injury based
56 on symptoms persisting > 24 hours or until death, and other etiologies excluded. (Note: CNS infarction includes
57 hemorrhagic infarctions, types I and II; see “Hemorrhagic Infarction”) [14-17].

58
59 Diagnostic catheter angiography – a minimally-invasive procedure involving percutaneous catheterization of any
60 of the arteries or veins involving the head and neck, brain, or spinal cord, performed with injection of a
61 radiocontrast agent and digital subtraction imaging.

62
63 Emergent large vessel occlusion (ELVO) – any acute occlusion of the internal carotid, proximal anterior cerebral,
64 proximal middle cerebral (M1 and M2 segments), proximal posterior cerebral, or vertebrobasilar arteries
65 documented by vascular imaging [18].

66
67 Hemorrhagic infarction (HI) – type I is defined by petechiae of blood along the margins of the infarction, whereas
68 type II has confluent petechiae within the infarction but without a space-occupying effect. HI is characterized by
69 its lack of mass effect [17].

70
71 Intracerebral hemorrhage (ICH) – A focal collection of blood within the brain parenchyma or ventricular system
72 that is not caused by trauma (Note: Intracerebral hemorrhage includes parenchymal hemorrhages after CNS
73 infarction, types I and II – see “Hemorrhagic Infarction.”) [17].

74
75 Ischemic stroke – An episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction
76 (Note: Evidence of CNS infarction is as defined previously.) [14-17].

77
78 Level of evidence – *Level A* evidence is high level evidence, most often derived from more than one randomized
79 controlled trial, a meta-analysis of high quality randomized controlled trials, or a randomized controlled trial
80 supported by a high quality registry. *Level B* evidence is moderate quality evidence, which may be derived from
81 randomized controlled trials or a well-designed non-randomized study, or a meta-analysis of such trials. *Level C*
82 evidence is considered limited or lower level evidence, based on observational trials or registries, meta-analyses
83 of such trials, or consensus of expert opinion based on experience [14,15].

84
85 Major complication – an event that results in admission to the hospital for therapy (for outpatient procedures), an
86 unplanned increase in the level of care, an unplanned increase in the length of hospital stay, or in permanent
87 adverse sequelae or death (see Appendix A).

88
89 Mechanical thrombectomy – a minimally-invasive procedure involving diagnostic catheter angiography followed
90 by direct removal of a thromboembolus from a target vessel using catheter-based techniques. Examples may
91 involve use of a stent retriever or an aspiration device, with or without maceration of the clot.

92

NOT FOR PUBLICATION, QUOTATION, OR CITATION

93 Minor complication – an event that results in no sequelae, or requires minimal therapy or a short hospital stay for
 94 observation (see Appendix A).

95
 96 Modified Rankin Scale (mRS) – a 7-point ordinal scale for measuring the degree of disability or dependence of
 97 patients who have suffered a stroke. It is a measure of overall functional outcome, rather than specific symptom
 98 severity. The scale ranges from 0 (no symptoms) to 6 (dead). (See Appendix)

99
 100 Modified thrombolysis in cerebral infarction (mTICI) score – a scale ranging from 0 to 3 that describes the degree
 101 of (re)perfusion of an artery past its initial occlusion and into its distal branches. A score of 0 indicates no
 102 perfusion, whereas a score of 3 indicates full reperfusion with filling of all the distal branches, including M3 and
 103 M4. (See Appendix)

104
 105 National Institutes of Health Stroke Scale (NIHSS) – a 42-point scale used to objectively and reproducibly
 106 quantify the severity of select symptoms caused by a stroke. The NIHSS is composed of 11 items, each of which
 107 scores a specific area of neurological function from 0 (not present) up to 4 (most severe). In the case of coma,
 108 certain scores (eg, those for ataxia) default to 0, so the maximum score in a comatose patient is 39 [19] (See
 109 Appendix).

110
 111 Parenchymal hemorrhage – type I is a confluent hemorrhage limited to < 30% of the infarcted area with only mild
 112 space-occupying effect, and type II is > 30% of the infarcted area and/or exerts a significant space-occupying
 113 effect. PH is characterized by the presence of mass effect, similar to the ICH definition of a focal collection of
 114 blood. Parenchymal hemorrhages should be considered ICHs [17].

115
 116 Stent retriever – a stent-like device that is used to remove a thromboembolus from an occluded vessel.

117
 118 Stroke caused by intracerebral hemorrhage – Rapidly developing clinical signs of neurological dysfunction
 119 attributable to a focal collection of blood within the brain parenchyma or ventricular system that is not caused by
 120 trauma [17].

121
 122 Subarachnoid hemorrhage (SAH) – Bleeding into the subarachnoid space (the space between the arachnoid
 123 membrane and the pia matter of the brain or spinal cord) [17].

124
 125 Threshold – a specific level of an indicator that should prompt the performance of a review

126
 127 Thrombolysis – a method of dissolving a thromboembolus within an occluded vessel using a fibrinolytic
 128 medication such as alteplase. At this time, alteplase is the only FDA-approved medication for use for acute stroke
 129 patients, and is only FDA-approved for intravenous use within 3 hours from time of onset or last known well. Per
 130 AHA/ASA guidelines, intravenous alteplase may be used up to 4.5 hours from onset or last known well in select,
 131 eligible patients. The intra-arterial administration of thrombolytics is well described, though considered “off-
 132 label” for acute stroke patients [15].

133 134 **III. INDICATIONS AND CONTRAINDICATIONS**

135 136 **A. Summary**

- 137 1. Class 1 recommendations based on *Level A* indications for endovascular revascularization include, but are
 138 not limited to:
 - 139 a. Treatment of adult patients with severe stroke symptoms (NIHSS \geq 6) caused by large vessel
 140 occlusion (ICA or M1 segment of the middle cerebral artery).
 - 141 b. Endovascular treatment which can be initiated within 6 hours of symptom onset.

142

NOT FOR PUBLICATION, QUOTATION, OR CITATION

- 143 2. Current contraindications for endovascular intervention based on a consensus of expert opinion include,
144 but are not limited to:
- 145 a. Evidence of a large irreversible infarction ($> 1/3$ of the middle cerebral artery territory or ASPECTS
146 < 6) in the territory of the index vessel.
 - 147 b. Severe baseline functional disability that would render the potential benefits of revascularization
148 negligible.
 - 149 c. Presence of intraparenchymal hemorrhage at the time of imaging evaluation.
- 150
- 151 3. There is mounting evidence that suggests that some patients not meeting Class 1 *Level A* eligibility
152 criteria may also benefit from treatment. Thus, it may be reasonable to treat some patients outside Class 1
153 recommendations.
154

B. Discussion

155 This section of the Practice Parameter concerns the clinical indications for endovascular revascularization
156 in patients with acute arterial ischemic stroke. Guidelines concerning the technical aspects of
157 revascularization are covered elsewhere.
158

159 The indications and contraindications described above have been endorsed by numerous professional
160 societies focused on cerebrovascular diseases comprising physicians in the fields of neuroradiology,
161 interventional radiology, neurointerventional surgery, neurosurgery and neurology. While these standards
162 are the current Class 1 recommendations, some publications indicate that up to 40% to 50% of the
163 patients treated are outside of the Class 1 recommendations of the AHA [20].
164
165

166 The inclusion and exclusion criteria are based on the following concepts:
167

- 168 • Patient selection for interventional stroke treatment requires the potential morbidity and mortality of
169 the untreated stroke to be greater than the risk of intervention. For example, a minor stroke that is
170 unlikely to cause significant long-term disability does not generally justify an invasive procedure that
171 may be more likely to cause greater harm than the stroke itself.
- 172 • NIHSS is the widely accepted clinical means of quantifying stroke severity. Current definition of
173 severe stroke is $\text{NIHSS} \geq 6$.
- 174 • Likelihood of a good clinical outcome in stroke depends on the timeliness of cerebral reperfusion.
175

Stroke Severity

176 The NIHSS cutoff determining “severe stroke symptoms” has evolved over time with a general trend
177 towards treating lower NIHSS. Early interventional stroke trials focused on intra-arterial thrombolysis
178 defined severe stroke as having an $\text{NIHSS} \geq 10$ [21]. This threshold was based on the low likelihood of a
179 good clinical outcome when patients at or above the threshold stroke severity were not treated.
180 Subsequent trials lower the definition of severe stroke to any stroke having an $\text{NIHSS} \geq 8$. This change
181 was also based on the observation that patients with strokes less severe than the selected severity
182 threshold had a reasonably good chance of a good clinical outcome if left untreated.
183
184

- 185 • Most recently, the definition of severe stroke for the purposes of endovascular therapy selection has
186 been lowered to $\text{NIHSS} \geq 6$ [3,5,22]. The presumption is patients with minor strokes defined as
187 $\text{NIHSS} \leq 5$, are less likely to have a poor neurological outcome than if they undergo an interventional
188 procedure.
189

NOT FOR PUBLICATION, QUOTATION, OR CITATION

190 Although this guideline is well founded in principle, there are some patients who present with minor
191 stroke symptoms due a large vessel occlusion that clinically worsen late in the course of their stroke due
192 to collateral failure. While such patients may have benefited from early treatment, they are often not
193 eligible for treatment when their symptoms worsen late in their clinical course because they fall outside
194 currently established temporal windows for therapeutic opportunity.

- 196 • Another category of patients with minor but stroke symptoms who may benefit from endovascular
197 revascularization are those patients in whom intravenous fibrinolysis is contraindicated. Given the
198 absence of any treatment options, such patients could reasonably be offered interventional therapy.
199 Unfortunately, it is not clear whether the risks of interventional treatment are less than the risks of
200 disease natural history in such patients.

201
202 Although further research is needed to determine when interventional therapy should be considered for
203 patients presenting with minor stroke symptoms, preliminary data suggest that patients with minor stroke
204 symptoms and large vessel occlusion may benefit from mechanical thrombectomy [23]. As the risk and
205 benefit of treatment evolve so might the pool of patients for whom thrombectomy may be considered
206 reasonable. For example, patients with isolated aphasia or hemianopia may be reasonable for treatment
207 despite lower NIH stroke scale scores [14].

208
209 Select patients with large vessel occlusion and an NIHSS ≤ 5 may still benefit from endovascular therapy.

210 Occlusion Location

211 As noted above, currently supported indications for interventional stroke therapy endorse specific
212 anatomical criteria involving large artery occlusions within the anterior circulation. These anatomical
213 criteria have been derived from a synthesis of data from large randomized clinical trials subjected to
214 rigorous peer review. There have not been large trials directed at acute ischemic stroke within the
215 posterior circulations (occlusion of basilar or vertebral artery), and *Level A* evidence for endovascular
216 treatment does not exist. However, treatment of these potentially devastating strokes is commonly
217 performed and should be considered on a case-by-case basis. Consequently, the authors of this document
218 feel that posterior circulation arterial ischemic stroke should be considered separately.

- 221 • There is consensus that patients with intracranial ICA or M1 segment MCA occlusion are appropriate
222 for endovascular treatment. However, it has been proposed that treatment of smaller vessels located
223 more distally in the anterior circulation should be considered reasonable, but there is significant
224 variability of opinion as to which vessels constitute reasonable targets for interventional therapy.
- 225 • Some arterial segments may be regarded as controversial. For example, Level A evidence currently
226 suggests that M2 lesions do not benefit in aggregate from treatment [24,25]. However, some post hoc
227 analyses suggest that there may be certain subgroups of patients with M2 occlusions that may benefit
228 from treatment. There is mounting evidence that the proximal M2 segments of the middle cerebral
229 arteries are suitable targets for endovascular revascularization [26-29].

230
231 One of the difficulties encountered in analysis of modern clinical trial data concerns the inconsistent
232 definition of proximal M2 occlusion. Case series and post hoc analyses of randomized clinical trial data
233 inconsistently show improved clinical outcomes in successfully revascularized M2 occlusions depending
234 on the size of the affected vascular territory. Nonetheless, there is an absence of Class I evidence
235 supporting the practice of M2 revascularization owing to the small number of patients with isolated M2
236 occlusions in recent positive clinical trials for interventional stroke therapy. However, consensus of expert
237 opinion increasingly supports the indication for interventional revascularization of a proximal M2
238 occlusion affecting perfusion of an entire frontal lobe, parietal lobe, and/or temporal lobe equivalent. Post
239 hoc analysis of IMS III data shows that M2 division occlusions affecting a cortical lobar equivalent

NOT FOR PUBLICATION, QUOTATION, OR CITATION

240 probably benefit from reperfusion therapy, but that smaller middle cerebral artery branch occlusions do
241 not [29]. Interventional treatment for occlusions of the anterior cerebral artery, posterior cerebral artery
242 and distal middle cerebral artery (M3 or M4 segments) would be considered controversial by many who
243 believe there is an insufficient added clinical benefit to justify the risk of an invasive intervention.
244

- 245 • The presumption is that many of these occlusions will recanalize either due to the effects of
246 intravenous thrombolytics, or the body’s natural thrombolytic process. In addition, the risk of
247 endovascular instrumentation increases as the cerebral artery becomes smaller, more distal, and
248 thinner walled [25].

249 Time

250 It is clear from all clinical stroke trials conducted to date that the likelihood of a good clinical outcome
251 depends on the timeliness of cerebral reperfusion. Data acquired from large populations of stroke patients
252 that have not been selected or stratified on the basis of cerebral perfusion imaging or collateral status have
253 shown that revascularization becomes futile if reperfusion is not achieved within 6 hours of symptom
254 onset.
255

- 256 • More recently, combined data from multiple randomized controlled stent retriever trials have
257 suggested that improved clinical outcomes are possible if cerebral reperfusion is achieved within 7.3
258 hours of symptom onset [30].
259

260 This futility threshold is considered by many to represent the time at which an intervention in progress
261 may be reasonably aborted, because the likelihood of harm exceeds the likelihood of benefit if reperfusion
262 is established beyond that temporal boundary. In such cases, reperfusion of irreversible infarction may
263 result in hemorrhage that contributes to a worsening of the patient’s clinical outcome. One notable
264 exception to this rule concerns the use of intra-arterial fibrinolytic drugs as a component of the
265 endovascular intervention. Prior studies have not established the safety of intra-arterial fibrinolytic
266 administration to stroke patients who are more than 6 hours from last seen normal [31].
267

268 Looking forward, there is mounting evidence that imaging, as opposed to time of symptom onset, can be
269 used to determine which patients are most likely to benefit from intervention. For example, for patients
270 with stroke of unknown onset (but > 8 hours) and patients with known stroke onset > 8 hours, the use of
271 imaging may allow selection of patients who benefit from mechanical thrombectomy [24,32].
272

- 273 • Imaging biomarkers of cerebral physiology may identify patients who may benefit from endovascular
274 therapy beyond 6 hours.
275

276 Infarct Size

277 Large irreversible infarction in territory of the index vessel is widely regarded as a contraindication to
278 endovascular revascularization. In such cases there is no expected benefit of revascularization, and the
279 likelihood of procedure related harm due to hemorrhagic reperfusion of the infarction is high. Infarction
280 involving $\geq 1/3$ of the middle cerebral artery territory has been considered a contraindication to
281 interventional treatment based on this principle. In an effort to standardize imaging criteria to support this
282 guideline, the ASPECT score was developed. Although an ASPECT score < 6 or other evidence of a large
283 core infarction at presentation is generally considered a contraindication to endovascular
284 revascularization, there is increasing controversy regarding the reliability of CT based ASPECT score to
285 determine the extent of irreversible infarction [33-35]. While there is likely a treatment effect from
286 endovascular revascularization in patients with lower ASPECT scores, this effect may not translate into
287

NOT FOR PUBLICATION, QUOTATION, OR CITATION

288 higher rates of functional independence mRS ($mRS \leq 2$) after treatment. Although diffusion weighted MR
289 imaging sequences are considered the standard for quantifying cerebral infarction, many factors continue
290 to prevent the widespread use of MR imaging to evaluate acute stroke patients in clinical practice.

291
292 CT perfusion or multiphase CT angiography may form part of the initial cross-sectional imaging work-up
293 of a stroke patient. CT perfusion and multiphase CTA were used to identify patients with large
294 irreversible infarction for exclusion in randomized trials [3,4,36]. There are differing methods and grading
295 scales for multiphase CTA. There is also recognized variation in CT perfusion map outputs among
296 different vendor software packages. The optimal use of these advanced imaging techniques is not
297 established by level I, Class A evidence. Based on currently published data, multiphase CTA and/or CT
298 perfusion results should not routinely be used as the criteria for inclusion or exclusion of a patient from
299 thrombectomy in current clinical practice, although these may be helpful in some situations as a
300 troubleshooting tool.

301
302 Significant subacute infarction or hemorrhage within the territory of an occluded target artery due to a
303 prior event predating the index presentation should be considered a contraindication to revascularization
304 of the occluded vessel. In such cases, reperfusion of affected brain may precipitate lethal or severely
305 disabling cerebral hemorrhage within the territory of the index vessel, negating any benefit of
306 revascularization.

307 Age

308 All clinical trials of endovascular therapy for acute stroke have been conducted in adult patients at least
309 18 years of age. On the other end of the age spectrum, three of the five landmark IA vs IV therapy
310 randomized trials published in 2015 did not exclude elderly patients (MR CLEAN, ESCAPE IA,
311 EXTEND-IA). We do not advocate for intra-arterial therapy being withheld from patients based on
312 advanced age alone, and additional study is required to determine the clinical efficacy of endovascular
313 revascularization in the very elderly (> 80 years) population.

- 314
- 315
- 316 • While patients < 18 years of age were not included in these clinical trials, endovascular stroke therapy
317 is considered reasonable in this population on a case-by-case basis according to expert consensus
318 [37].
- 319 • Endovascular therapy should not be withheld based on advanced age alone.
- 320

321 For the pregnant or potentially pregnant patient, see the [ACR–SPR Practice Parameter for Imaging Pregnant or](#)
322 [Potentially Pregnant Adolescents and Women with Ionizing Radiation](#) [38].

323 **IV. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL**

324
325 See the [ACR–ASNR–SIR–SNIS Practice Parameter for the Performance of Diagnostic Cervicocerebral Catheter](#)
326 [Angiography in Adults](#) [39].

327 **A. Physician**

328
329 Physicians providing emergent intra-arterial intervention for acute ischemic stroke are required to have
330 appropriate training and experience for the performance of neuroangiography and neuroendovascular therapy,
331 which are essential for safe and efficient stroke patient management. While the physician qualifications below are
332 tailored towards new practitioners, it should be recognized that there are current practitioners (who may be board
333 certified or board eligible in either radiology, neurology or neurosurgery) having trained prior to, or outside of,
334 established formal neuroendovascular training programs, and having acquired the necessary skills listed below to
335 perform safe and effective intra-arterial stroke treatment. Nonetheless, all neuroendovascular specialists are
336
337

NOT FOR PUBLICATION, QUOTATION, OR CITATION

338 required to participate in maintenance of certification and maintenance of qualification requirements, as listed
339 below.

340

341 Endovascular embolectomy and revascularization in acute stroke examinations must be performed by or under the
342 supervision of and interpreted by a physician who has met the following qualifications [ACR-ASNR-SIR-SNIS](#)
343 [Practice Parameter for the Performance of Diagnostic Cervicocerebral Catheter Angiography in Adults](#) [39] as
344 well as the qualifications below:

345

346 1. Accreditation Council for Graduate Medicine Education (ACGME) or Royal College of Physicians and
347 Surgeons of Canada (RCPSC) accredited residency or fellowship training (in radiology, neurology or
348 neurosurgery) which should include documented training in the diagnosis and management of acute
349 stroke. Those physicians who did not have adequate such training during their residencies must spend an
350 additional period (to complete at least one year) of training in clinical neurosciences and neuroimaging,
351 focusing on the diagnosis and management of acute stroke, the interpretation of cerebral arteriography
352 and neuroimaging.

353

or

354 2. Dedicated training in Interventional Neuroradiology (also termed Endovascular Neurosurgery or
355 Interventional Neurology) under the direction of a Neurointerventionalist (with neuroradiology,
356 neurology or neurosurgical training background), at a high-volume center. It is preferred that this is a
357 dedicated time (minimum of one year), which occurs after graduating from residency (i.e., a fellowship).
358 A training program accredited by a national accrediting body is also strongly preferred but not required.
359 Within these programs, specific training for intra-arterial therapy for acute ischemic stroke should be
360 performed, including obtaining appropriate access even in challenging anatomy, microcatheter navigation
361 in the cerebral circulation, knowledge and training of the use of stroke specific devices and complication
362 avoidance and management. While various national standards will have differing procedure requirements,
363 we encourage practitioners to meet their national minimum procedural and training standards. Non-
364 accredited fellowships are also expected to have adequate training to meet minimum procedure
365 requirements.

366

367 3. Physicians meeting all of the qualifications in 1 or 2 above must have the following:

368

369 Documentation of competency in all aspects of the procedure and pre- and post-procedure care by the use
370 of objective outcome-based tools related to angiographic experience is necessary. Attestation of
371 competency by a qualified neurointerventionalist who has observed the physician during the performance
372 of thrombectomy procedures is required.

373

374 For previously credentialed physicians who perform intra-arterial catheter-directed stroke procedures at
375 their local institutions, they should have documented procedural and clinical outcomes that meet national
376 standards and published evidence-based guidelines.

377

378 The written substantiation should come from the chief of interventional radiology, the chief of
379 neuroradiology, the chief of interventional neuroradiology, or the chair of the department of the institution
380 in which the physician will be providing these services.² Substantiation could also come from a prior
381 institution in which the physician provided the services, but only at the discretion of the current
382 interventional, neurointerventional, or neuroradiology chief or of the chair who solicits the additional
383 input.

²At institutions in which there is joint (dual) credentialing across departments doing like procedures, this substantiation of experience should be done by the chairs of both departments to ensure equity of experience among practitioners when their training backgrounds differ.

NOT FOR PUBLICATION, QUOTATION, OR CITATION

384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430

Maintenance of Competence

Physicians must perform a sufficient number of endovascular embolectomy and revascularization in acute stroke procedures to maintain their skills, with acceptable success and complication rates according to this parameter. Individual physician outcomes should conform to national standards and institutional requirements. In addition, the physician should participate in an ongoing quality assurance and improvement program. The goals of this quality assurance program for stroke therapy would be to monitor outcomes both in the periprocedural period and at 90 days. The quality assurance program must review all emergency interventional stroke therapy patients. In addition, physicians and facilities should participate in a quality improvement registry. Participation in a national registry is encouraged. Outcomes should be tracked and recorded. Threshold levels for recanalization and complication rates have been established by society consensus [40,41]. Based on these references we suggest the following as a minimum, but the indicators and thresholds are currently being revised and will replace the current thresholds.

1. Successful recanalization (modified TIC1 2b or 3) in at least 60% of cases.
2. Embolization to new territory of < 15%.
3. Symptomatic intracranial hemorrhage (ie, Parenchymal Hematoma on imaging with clinical deterioration) rate < 12% [41,42].

Continuing Medical Education

The physician’s continuing education should be in accordance with the [ACR Practice Parameter for Continuing Medical Education \(CME\)](#) [43].

B. Qualified Medical Physicist

A Qualified Medical Physicist is an individual who is competent to practice independently in one or more of the subfields in medical physics. The American College of Radiology considers certification, continuing education, and experience in the appropriate subfield(s) to demonstrate that an individual is competent to practice in one or more of the subfields in medical physics, and to be a Qualified Medical Physicist. The ACR strongly recommends that the individual be certified in the appropriate subfield(s) by the American Board of Radiology (ABR), the Canadian College of Physics in Medicine, or by the American Board of Medical Physics (ABMP).

A Qualified Medical Physicist should meet the [ACR Practice Parameter for Continuing Medical Education \(CME\)](#). (ACR Resolution 17, 1996 – revised in 2012, Resolution 42) [43]

The appropriate subfield of medical physics for this parameter is Diagnostic Medical Physics. (Previous medical physics certification categories including Radiological Physics, Diagnostic Radiological Physics, and Diagnostic Imaging Physics are also acceptable.)

C. Registered Radiologist Assistant

A registered radiologist assistant is an advanced level radiographer who is certified and registered as a radiologist assistant by the American Registry of Radiologic Technologists (ARRT) after having successfully completed an advanced academic program encompassing an ACR/ASRT (American Society of Radiologic Technologists) radiologist assistant curriculum and a radiologist-directed clinical preceptorship. Under radiologist supervision,

NOT FOR PUBLICATION, QUOTATION, OR CITATION

431 the radiologist assistant may perform patient assessment, patient management, and selected examinations as
 432 delineated in the Joint Policy Statement of the ACR and the ASRT titled “Radiologist Assistant: Roles and
 433 Responsibilities” and as allowed by state law. The radiologist assistant transmits to the supervising radiologists
 434 those observations that have a bearing on diagnosis. Performance of diagnostic interpretations remains outside the
 435 scope of practice of the radiologist assistant. (ACR Resolution 34, adopted in 2006)

436

437 D. Radiologic Technologist

438

- 439 1. The technologist, together with the physician and nursing personnel, should be responsible for patient
 440 comfort and safety. The technologist should be able to prepare and position³ the patient for the
 441 arteriographic procedure and, together with the nurse, monitor the patient during the procedure. The
 442 technologist should obtain the imaging data in a manner prescribed by the supervising physician. The
 443 technologist should also perform regular quality control testing of the equipment under supervision of the
 444 physicist.
- 445 2. Technologist should be properly trained in the use of the arteriographic equipment and endovascular
 446 devices employed in the institution. They should demonstrate appropriate knowledge of patient
 447 positioning, endovascular devices, angiographic imaging and archiving, radiation protection angiographic
 448 contrast injectors, angiographic supplies, and physiologic monitoring equipment. Certification as a
 449 vascular and interventional radiologic technologist is one measure of appropriate training. The
 450 technologists should be trained in cardiopulmonary resuscitation and in the location and function of the
 451 resuscitation equipment.
- 452 3. Technologists should be certified by the American Registry of Radiologic Technologists (ARRT) or have
 453 an unrestricted state license and documented training and experience in catheter cerebral arteriography.

454

455 E. Sedation and Analgesia Services

456

457 If the patient is to undergo procedural sedation, a licensed provider must monitor the patient as his/her
 458 primary responsibility and in accordance with the [ACR–SIR Practice Parameter for Sedation/Analgesia](#) [44].
 459 Individuals should be trained in the location of and the use of the facility’s resuscitation equipment and in
 460 institutional protocols for code team alerts. Licensed providers must be privileged by the institution to
 461 administer sedation.

462

463 F. Nursing Services

464

465 Nursing services are necessary for monitoring the patient during the procedure in cases in which a qualified
 466 anesthesiologist is not involved.

467

468

³The American College of Radiology approves of the practice of certified and/or licensed radiologic technologists performing fluoroscopy in a facility or department as a positioning or localizing procedure only, and then only if monitored by a supervising physician who is personally and immediately available*. There must be a written policy or process for the positioning or localizing procedure that is approved by the medical director of the facility or department/service and that includes written authority or policies and processes for designating radiologic technologists who may perform such procedures. (ACR Resolution 26, 1987 – revised in 2007, Resolution 12m)

*For the purposes of this parameter, “personally and immediately available” is defined in manner of the “personal supervision” provision of CMS—a physician must be in attendance in the room during the performance of the procedure. Program Memorandum Carriers, DHHS, HCFA, Transmittal B-01-28, April 19, 2001.

NOT FOR PUBLICATION, QUOTATION, OR CITATION469 **V. SPECIFICATIONS OF THE EXAMINATION**

470

471 **A. Facilities and Resources**

472

473 Endovascular therapy requires the patient to be at an experienced stroke center with rapid access to cerebral
474 angiography and qualified neurointerventionalists. Although complications of endovascular stroke intervention
475 rarely require urgent surgery, angiographic procedures should be performed in an environment where necessary
476 surgical intervention can be instituted promptly. This would be an acute-care hospital with adequate
477 neurointerventional, neurosurgery, vascular surgery, anesthesiology, and ancillary support [40].
478

479

B. Preprocedure Care

480

a. Clinical Evaluation

481

i. Clinical evaluation necessary for therapeutic decision-making in the acute phase should be performed
482 as appropriate, including, but not necessarily limited to, the following:

483

1. Relevant history of present illness, including time of the patient was last known to be well

484

2. Pertinent co-morbidities and recent medications

485

3. Assessment of pre-morbid functioning including determination of mRS

486

4. Assessment of neurological impairment, including determination of NIHSS

487

5. Assessment of hemodynamic and airway stability, including basic vital signs

488

ii. Clinical evaluation in the acute phase should be performed expediently. Any clinical evaluation that is
489 not necessary for decision-making in the acute phase but would delay acute therapies should be
490 deferred.

491

b. Serological Evaluation

492

i. Serological evaluation necessary for therapeutic decision-making in the acute phase should be
493 performed as appropriate, which may include but is not necessarily limited to, measurement of
494 hemoglobin, hematocrit, platelet count, electrolytes, and coagulation parameters.

495

ii. Serological evaluation in the acute phase should be performed expediently. Any serological tests that
496 are not necessary for decision-making in the acute phase but would delay acute therapies should be
497 deferred.

498

c. Radiological Evaluation

499

i. Neurological imaging may be reasonably performed using CT or MRI, as dictated by institutional
500 protocol, resource availability, and patient condition.

501

ii. At a minimum, neurological imaging should be sufficient to allow identification of intracranial
502 hemorrhage, extent of completed infarction, and location of vessel occlusion.

503

iii. Additional neurological imaging for assessment of ischemic penumbra, such as perfusion imaging or
504 multiphase CT angiography, may be performed as necessary.

505

iv. Neurological imaging necessary for therapeutic decision-making in the acute phase should be
506 performed expediently. To the extent possible, effort should be taken to minimize the time elapsed
507 between patient arrival and completion of neurological imaging. Any radiological studies that are not
508 necessary for decision-making in the acute phase but would delay acute therapies should be deferred.

509

v. Administration of iodinated contrast should not be delayed on account of unavailable serum
510 creatinine result [45].

511

d. Informed Consent

512

i. Informed consent must be in compliance with all state or federal laws, as appropriate, and the [ACR–
513 SIR Practice Parameter on Informed Consent for Image-Guided Procedures](#) [46].

514

e. Transport

515

i. Once the decision has been made to perform endovascular treatment of acute ischemic stroke,
516 transport of the patient to an appropriately equipped procedure room should be performed
517 expediently. To the extent possible, effort should be taken to minimize the time elapsed between
518 patient arrival and arterial puncture.

NOT FOR PUBLICATION, QUOTATION, OR CITATION

519

520 C. Intra-procedure Care

521

522 As with all aspects of patient care in acute stroke, patient safety and time to recanalization are the primary goals.
523 Controversy continues with regard to the appropriate approach to sedation and anesthesia with respect to the acute
524 stroke patient. We recommend that the choice and level of sedation/anesthesia be guided by the patient's
525 condition and resources available. Further, patients undergoing endovascular intervention for acute ischemic
526 stroke should be monitored and managed in accordance with the Society for Neuroscience in Anesthesiology and
527 Critical Care Expert Consensus Statement [47]. If the patient is to undergo procedural sedation, a licensed
528 provider must monitor the patient as his/her primary responsibility. This person must maintain an appropriate
529 record of intraprocedural monitoring and care, as described in the [ACR–SIR Practice Parameter for
530 Sedation/Analgesia](#) [44].

531

532 The team required to safely and expeditiously perform cerebrovascular recanalization should be qualified and
533 experienced as outlined in section IV.A. Members of this team should assist in performing, imaging, and
534 archiving the procedure as needed.

535

536 To expedite recanalization, all nursing, technologist, sedation provider, and interventionalist duties that can be
537 completed prior to patient arrival should be performed. In addition, we recommend that each member of the team
538 familiarize themselves with the patient's medical history (including advanced directives), the patient's
539 presentation and the patient's current condition prior to the patient arriving in the angiography suite.

540

541 Upon patient arrival in the angiography suite, we recommend clear delegation of responsibilities to team members
542 to allow parallel systems processes and reduce procedure time. In addition to documentation of patient vital signs
543 and medications during the procedure, we should include intra-procedural documentation include, at a minimum:
544 angiography suite arrival time, arterial access time, time of first access to the site of occlusion, number of passes
545 required to achieve recanalization, and time to recanalization with the corresponding TICI score. Documentation
546 should meet the requirements of the quality improvement program described in section X and comprehensive
547 stroke center requirements.

548

549 The choice of access, guiding catheter, use of aspiration and embolic retrieval device are left to the
550 interventionalist's clinical judgment and personal preference. The use of intra-arterial fibrinolysis should be
551 reserved for specific patient populations; however, these data are derived from clinical trials that no longer reflect
552 current practice. In addition, a clinically beneficial dose of intra-arterial r-tPA is not established, and r-tPA does
553 not have US Food and Drug Administration approval for intra-arterial use. Intra-arterial fibrinolysis should not be
554 performed in patients who are candidates for primary mechanical thrombectomy. [40]. The effectiveness and
555 utility of additional intra-arterial medications, such as anti-platelet medications, has not been established. We
556 recommend avoiding the use of cervicocerebral stents in the acute setting unless deemed absolutely necessary due
557 to the hemorrhagic risks of antiplatelet medications in the setting of the acute ischemic stroke.

558

559 D. Postprocedure Care

560

561 There is no definitive guideline for post procedural care after endovascular treatment of acute stroke due to
562 ELVO. Despite that, patients who undergo endovascular treatment, in general, require special post procedural
563 attention other than the expected access site and lower or upper extremity (depending on the access: femoral,
564 radial, brachial, carotid) checks. This is usually accomplished in a multidisciplinary team approach, along with
565 neurologists, intensive care physicians and other specialties (hospitalist, cardiologist if needed). Ideally these
566 patient should be admitted to a Neuro Intensive Care Unit (NeuroICU) or to a dedicated Stroke Unit where vital

NOT FOR PUBLICATION, QUOTATION, OR CITATION

567 signs and neurological examination can be performed every 1h. It is a reasonable approach to keep these patients
568 in NeuroICU/Stroke Unit care level for 24h. Some patients with rapid neurological improvement and minor
569 residual deficits post mechanical thrombectomy may be transferred to the stroke floor to continue stroke work up,
570 and physical and occupational therapy. Patients with severe strokes may have decreased level of consciousness
571 and may require (if not already) endotracheal intubation for airway protection. In these cases neurological
572 examination is limited and serial imaging may be necessary within the first 12 to 72h to assess stroke extension,
573 mass effect, and the need for decompressive craniectomy.

574
575 Blood pressure (BP) control after endovascular treatment is important, however, the ideal numbers are still a
576 matter of debate. Higher BP may increase the risk of hemorrhagic conversion and lower BP may increase the risk
577 of infarct expansion in hypoperfusion states [48-50]. The existing data in regards to blood pressure parameters in
578 acute stroke derives from guidelines for IV thrombolytic therapy. According to AHA/ASA guidelines [14], the
579 recommended blood pressure target post IV tPA is SBP < 180 mmHg and DBP < 105 mmHg for 24h. However, it
580 is questionable if these parameters should be applied after successful endovascular treatment (TICI 2b and 3)
581 since the complete or near-complete reperfusion of the cerebral tissue associated with higher BP parameters may
582 increase the theoretical risk of hemorrhage. In these cases, it seems reasonable to consider lower BP parameters
583 despite the lack of evidence.

584
585 A significant number of patients with acute stroke from ELVO have a cardioembolic source such as atrial
586 fibrillation as culprit. In these patients anticoagulation should be started as soon as possible [51]. The timing of
587 when to restart or start these medications is controversial due to the risk of hemorrhagic transformation inherent to
588 infarcted brain parenchyma. Evidence is lacking in this aspect; however, based on expert opinion, a common rule
589 is to start anticoagulation in 72h after small infarct; 7 days and 14 days after moderate and large size infarcts
590 respectively [51].

591
592 In regards to post procedural laboratory results, patients with acute stroke benefit from tight glycemic control. The
593 Glycemia in Acute Stroke study showed that hyperglycemia (> 155 mg/dL) was associated with increased odds of
594 poor outcome and death at 3 months [52]. The goal of glycemic control should be normoglycemia (80 to 120
595 mg/dL). The AHA/ASA guidelines recommend treatment of hypoglycemia (< 60 mg/dL). For patients with
596 hyperglycemia it is recommended to achieve blood glucose levels in a range of 140 to 180 mg/dL [14]. Another
597 aspect to be aware is the risk of contrast-induced nephropathy since many of these patients are elderly and some
598 patients may already present with decreased renal function. Temperature control is also important and sources of
599 hyperthermia ($t > 38C$) should be identified and treated [14]. Post procedural lab work in general demonstrate
600 some degree of hemodilution; however, since most of the endovascular stroke treatments performed currently
601 require the use of large sheaths and may have been performed in patients that have received thrombolytic therapy
602 or anticoagulation, one should be attentive to signs of possible access site or retroperitoneal hematoma. Despite
603 the lack of evidence specifically in acute stroke patients treated with endovascular techniques, a systematic review
604 of blood transfusions in neurocritical care patients found that hemoglobin concentrations as low as 7 g/dL are
605 generally well tolerated [53,54].

606
607 **VI. DOCUMENTATION**
608

609 Reporting should be in accordance with the [ACR–SIR–SPR Practice Parameter for the Reporting and Archiving](#)
610 [of Interventional Radiology Procedures](#) [55].

611
612 Specific pre-procedure information that should be available in the medical record includes clinically significant
613 history, including indications for the procedure; pre-morbid functioning, ideally using mRS; degree of
614 neurological impairment and other pertinent physical examination findings prior to treatment, including
615 determination of NIHSS; and findings of pertinent diagnostic imaging studies. Specific post-procedure

NOT FOR PUBLICATION, QUOTATION, OR CITATION

616 information that should be available within the medical record includes extent of angiographic recanalization,
617 ideally using mTICI score, and degree of neurological impairment following treatment, including determination
618 of NIHSS within 24 hours of treatment and mRS at 90 days after treatment, when possible. Documentation should
619 meet the requirements of the quality improvement program described in section X.

VII. EQUIPMENT SPECIFICATION

622 There are multiple technical requirements that are necessary to ensure safe and successful endovascular treatment
623 of acute ischemic stroke. These include adequate arteriographic and interventional equipment and institutional
624 facilities, physiologic monitoring equipment, and support personnel.

A. Procedural Equipment and Facilities

626 The following are considered the minimum equipment requirements for performing endovascular treatment of
627 acute ischemic stroke. In planning facilities for these procedures, equipment and facilities more advanced than
628 those outlined below may be desired to improve outcomes and reduce duration of the procedures. In general, at a
629 minimum, the facility should include:

- 633 1. A high resolution flat panel detector (preferred) or image intensifier and image monitor with digital
634 subtraction angiographic and roadmapping capabilities. Biplane capability is desirable to guide
635 interventions and to reduce contrast injections. Equipment requirements are more stringent than those for
636 the performance of diagnostic cervicocerebral angiography due to the higher complexity and risk of
637 interventional procedures. Digital angiographic systems without subtraction and roadmapping capability
638 and older film based systems are therefore unacceptable for these procedures, except in the rare event that
639 transfer to another system or institution with such capabilities would severely delay care. If such a system
640 is employed as a back-up for a more capable system, the actual use for endovascular treatment of acute
641 ischemic stroke should be monitored with the expectation that this should be very rare. Imaging data
642 should be acquired and permanently recorded on an archival digital storage medium that allows retrieval
643 and review. It is highly desirable to be able to record and archive images used for guidance and decision
644 making during the procedure, including last-image-hold images and fluoroscopy loops. Imaging, image
645 recording, and archiving must be consistent with the ALARA radiation safety philosophy. Use of last
646 image hold, fluoroscopy loops, and pulsed fluoroscopy are recommended for dose reduction. Small focal
647 spots for high-resolution imaging and adjustable frame rates are necessary. The available field of view
648 (FOV) should be able to fit the whole head in frontal and lateral projections, with acknowledgement that
649 some biplane neuroangiography systems employ a slightly smaller lateral detector to facilitate multi-angle
650 oblique imaging. Modern low-dose DSA settings should be applied when possible, but high-dose settings
651 should be available for situations that require increased diagnostic sensitivity. Rotational angiography and
652 flat panel detector CT imaging are desirable to facilitate interventions and identify intraprocedural
653 cerebral hemorrhage, respectively.
- 654 2. Adequate interventional and angiographic supplies such as embolectomy devices (eg, stent retrievers and
655 aspiration catheters), vascular stents, embolic protection devices, angioplasty balloons, catheters,
656 guidewires, needles, flush systems, hemostatic devices, introducer sheaths and biohazard disposal
657 systems.
- 658 3. An angiographic injector capable of varying injection volumes and rates with appropriate safety
659 mechanisms (pressure monitoring) to prevent over injection.

NOT FOR PUBLICATION, QUOTATION, OR CITATION

- 664 4. An angiography suite large enough to allow uncomplicated patient transfer from the bed to table and to
 665 allow room for the procedure table, monitoring equipment, and other hardware such as intravenous
 666 pumps, respirators, anesthesia team and equipment, oxygen tanks, suction, and gases. There should be
 667 adequate space for the operating team to work unencumbered on either side of the patient and for the
 668 circulation of other technical staff in the room without contaminating the sterile conditions.
 669
- 670 5. An area within the institution appropriate for patient evaluation and preparation prior to the procedure.
 671 Appropriate emergency equipment and medications must be immediately available to treat adverse
 672 reactions associated with administered medications and/or procedural complications. Immediate access to
 673 a CT scanner is necessary to evaluate for potential cerebral hemorrhage, edema and hydrocephalus. The
 674 equipment should be monitored and medications inventoried for drug expiration dates on a regular basis.
 675 The equipment, medications, and other emergency support must also be appropriate for the range of ages
 676 and sizes in the patient population.
 677

B. Physiologic Monitoring and Resuscitation Equipment

- 680 1. Appropriate equipment should be present in the angiography suite to allow for monitoring the patient's
 681 heart rate, cardiac rhythm, and blood pressure. For facilities using sedation, a pulse oximeter must be
 682 available (see the [ACR–SIR Practice Parameter for Sedation/Analgesia](#) [44]). Appropriate equipment and
 683 supplies to support the safe performance of general anesthesia should be available.
 684
- 685 2. Emergency resuscitation equipment and drugs should be immediately available and include the following:
 686 a defibrillator, oxygen supply and appropriate tubing and delivery systems, suction equipment, tubes for
 687 endotracheal intubation, laryngoscope, ventilation bag-valve-mask apparatus, and central venous line sets.
 688 Drugs for treating cardiopulmonary arrest, contrast reaction, vasovagal reactions, and ventricular
 689 arrhythmias, as well as drugs for narcotic or benzodiazepine reversal and protamine if heparin is
 690 administered. Resuscitation equipment should be monitored and checked routinely in compliance with
 691 institutional policies.
 692

VIII. RADIATION SAFETY IN IMAGING

695 Radiologists, medical physicists, registered radiologist assistants, radiologic technologists, and all supervising
 696 physicians have a responsibility for safety in the workplace by keeping radiation exposure to staff, and to society
 697 as a whole, “as low as reasonably achievable” (ALARA) and to assure that radiation doses to individual patients
 698 are appropriate, taking into account the possible risk from radiation exposure and the diagnostic image quality
 699 necessary to achieve the clinical objective. All personnel that work with ionizing radiation must understand the
 700 key principles of occupational and public radiation protection (justification, optimization of protection and
 701 application of dose limits) and the principles of proper management of radiation dose to patients (justification,
 702 optimization and the use of dose reference levels)

703 http://www-pub.iaea.org/MTCD/Publications/PDF/Pub1578_web-57265295.pdf.

705 Nationally developed guidelines, such as the ACR's [Appropriateness Criteria](#)[®], should be used to help choose the
 706 most appropriate imaging procedures to prevent unwarranted radiation exposure.
 707

708 Facilities should have and adhere to policies and procedures that require varying ionizing radiation examination
 709 protocols (plain radiography, fluoroscopy, interventional radiology, CT) to take into account patient body habitus
 710 (such as patient dimensions, weight, or body mass index) to optimize the relationship between minimal radiation
 711 dose and adequate image quality. Automated dose reduction technologies available on imaging equipment should
 712 be used whenever appropriate. If such technology is not available, appropriate manual techniques should be used.
 713

NOT FOR PUBLICATION, QUOTATION, OR CITATION

714 Additional information regarding patient radiation safety in imaging is available at the Image Gently® for children
715 (www.imagegently.org) and Image Wisely® for adults (www.imagewisely.org) websites. These advocacy and
716 awareness campaigns provide free educational materials for all stakeholders involved in imaging (patients,
717 technologists, referring providers, medical physicists, and radiologists).

718
719 Radiation exposures or other dose indices should be measured and patient radiation dose estimated for
720 representative examinations and types of patients by a Qualified Medical Physicist in accordance with the
721 applicable ACR Technical Standards. Regular auditing of patient dose indices should be performed by comparing
722 the facility’s dose information with national benchmarks, such as the ACR Dose Index Registry, the NCRP
723 Report No. 172, Reference Levels and Achievable Doses in Medical and Dental Imaging: Recommendations for
724 the United States or the Conference of Radiation Control Program Director’s National Evaluation of X-ray
725 Trends. (ACR Resolution 17 adopted in 2006 – revised in 2009, 2013, Resolution 52).

IX. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION

730 Policies and procedures related to quality, patient education, infection control, and safety should be developed and
731 implemented in accordance with the ACR Policy on Quality Control and Improvement, Safety, Infection Control,
732 and Patient Education appearing under the heading *Position Statement on QC & Improvement, Safety, Infection*
733 *Control, and Patient Education* on the ACR website (<http://www.acr.org/guidelines>).

734
735 The data developed through these policies and procedures should be used in conjunction with the thresholds
736 described in section X below to assess diagnostic cervicocerebral catheter angiographic procedural efficacy and
737 complication rates and, as defined in those sections, to trigger institutional review when the thresholds defined in
738 those sections are exceeded.

X. QUALITY IMPROVEMENT

741
742 Clinical outcomes for endovascular acute ischemic stroke interventions depend on both individual and facility
743 performance. A quality improvement program is necessary to identify performance results and opportunities for
744 improvement to reduce treatment times and improve revascularization rates. A multisociety and multispecialty
745 consensus paper provides indicators and thresholds for performance [41]. Physicians and facilities that provide
746 these stroke interventions should meet these thresholds. These indicators and thresholds are being revised to
747 include the most recent trial results.

ACKNOWLEDGEMENTS

751 This parameter was revised according to the process described under the heading *The Process for Developing*
752 *ACR Practice Parameters and Technical Standards* on the ACR website (<http://www.acr.org/guidelines>) by the
753 Committee on Practice Parameters - Neuroradiology of the ACR Commission on Neuroradiology and the
754 Committee on Practice Parameters - Interventional and Cardiovascular Radiology of the ACR Commission on
755 Interventional & Cardiovascular Radiology, in collaboration with the ASNR, the SNIS, and the SIR.

756
757

NOT FOR PUBLICATION, QUOTATION, OR CITATION

758 Collaborative Committee – members represent their societies in the initial and final revision of this practice
 759 parameter
 760

ACR

Steven W. Hetts, MD, Chair
 Todd Abruzzo, MD
 John D. Barr, MD, FACR, FSIR, FAHA
 Kristine A. Blackham, MD
 Lotfi Hacein-Bey, MD
 Jeremy J. Heit, MD, PhD
 John E. Jordan, MD, MPP, FACR
 Akash P. Kansagra, MD, MS

ASNR

Matthew R. Amans, MD, MSc
 Edward D. Greenberg, MD
 Grant J. Linnell, DO, FRCPSC
 Franklin A. Marden, MD, FAHA, FAAN
 Rohan Samant, MD, MBA
 Fabio Settecase, MD, MSc

761

SIR

Jeffrey S. Carpenter, MD
 Joseph J. Gemmete, MD, FACR, FSIR, FAHA
 Martin G. Radvany, MD, FSIR
 David Sacks, MD, FACR, FSIR
 Venu Vadlamudi, MD

SNIS

Guilherme Dabus, MD
 Joshua A. Hirsch, MD, FACR, FSIR
 Richard P. Klucznik, MD, FACR
 Ryan A. McTaggart, MD
 Ansaar Rai, MD

762

Committee on Practice Parameters – Neuroradiology

(ACR Committee responsible for sponsoring the draft through the process)

John E. Jordan, MD, MPP, FACR, Chair
 Raymond K. Tu, MD, FACR, Vice Chair
 Kristine A. Blackham, MD
 Brian A. Conley, MD
 H. Simms Hardin, IV, MD
 Steven W. Hetts, MD
 Jacqueline C. Junn, MD
 Stephen A. Kieffer, MD, FACR

Robert J. McDonald, MD
 Alexander M. McKinney, IV, MD
 David M. Mirsky, MD
 Robin J. Mitnick, MD
 A. Orlando Ortiz, MD, MBA, FACR
 Glenn H. Roberson, MD
 Lubdha Shah, MD
 Max Wintermark, MD

763

Committee on Practice Parameters – Interventional and Cardiovascular Radiology

(ACR Committee responsible for sponsoring the draft through the process)

Clayton K. Trimmer, DO, FACR, FAOCR, FSIR, Chair
 Chaitanya Ahuja, MBBS
 Drew M. Caplin, MD
 Douglas M. Coldwell, MD, PhD
 Kevin W. Dickey, MD
 Joshua A. Hirsch, MD, FACR, FSIR
 Kelvin Hong, MD, FSIR
 Elizabeth A. Ignacio, MD, FSIR
 Sanjeeva P. Kalva, MD, FSIR

Claire Kaufman, MD
 Minhajuddin S. Khaja, MD, MBA
 Margaret Hsin-Shung Lee, MD
 Susan K. O'Horo, MD, FSIR
 John D. Prologo, MD
 Stephen P. Reis, MD
 Beth A. Schueler, PhD, FACR, FAAPM
 Sanjit Tewari, MD

764

765

766

767

768

Alexander M. Norbash, MD, FACR, Chair, Commission on Neuroradiology
 Philip S. Cook, MD, FACR, FSIR, Chair, Commission on Interventional and Cardiovascular Radiology
 Jacqueline Anne Bello, MD, FACR, Chair, Commission on Quality and Safety
 Matthew S Pollack, MD, FACR, Chair, Committee on Practice Parameters and Technical Standards

NOT FOR PUBLICATION, QUOTATION, OR CITATION769 **REFERENCES**

770

- 771 1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From
772 the American Heart Association. *Circulation*. 2017;135(10):e146-e603.
- 773 2. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic
774 stroke. *The New England journal of medicine*. 2015;372(1):11-20.
- 775 3. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-
776 imaging selection. *The New England journal of medicine*. 2015;372(11):1009-1018.
- 777 4. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of
778 ischemic stroke. *The New England journal of medicine*. 2015;372(11):1019-1030.
- 779 5. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke.
780 *The New England journal of medicine*. 2015;372(24):2296-2306.
- 781 6. Saver JL, Goyal M, Bonafe A, et al. Solitaire with the Intention for Thrombectomy as Primary Endovascular
782 Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled,
783 multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute
784 ischemic stroke. *International journal of stroke : official journal of the International Stroke Society*.
785 2015;10(3):439-448.
- 786 7. Rai AT, Seldon AE, Boo S, et al. A population-based incidence of acute large vessel occlusions and
787 thrombectomy eligible patients indicates significant potential for growth of endovascular stroke therapy in the
788 USA. *Journal of neurointerventional surgery*. 2017;9(8):722-726.
- 789 8. Jovin TG, Saver JL, Ribo M, et al. Diffusion-weighted imaging or computerized tomography perfusion
790 assessment with clinical mismatch in the triage of wake up and late presenting strokes undergoing
791 neurointervention with Trevo (DAWN) trial methods. *International journal of stroke : official journal of the*
792 *International Stroke Society*. 2017;12(6):641-652.
- 793 9. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed
794 tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study
795 Group. Alberta Stroke Programme Early CT Score. *Lancet*. 2000;355(9216):1670-1674.
- 796 10. Barber PA, Hill MD, Eliasziw M, et al. Imaging of the brain in acute ischaemic stroke: comparison of
797 computed tomography and magnetic resonance diffusion-weighted imaging. *Journal of neurology,*
798 *neurosurgery, and psychiatry*. 2005;76(11):1528-1533.
- 799 11. Finlayson O, John V, Yeung R, et al. Interobserver agreement of ASPECT score distribution for noncontrast
800 CT, CT angiography, and CT perfusion in acute stroke. *Stroke*. 2013;44(1):234-236.
- 801 12. Kosior RK, Lauzon ML, Steffenhagen N, Kosior JC, Demchuk A, Frayne R. Atlas-based topographical
802 scoring for magnetic resonance imaging of acute stroke. *Stroke*. 2010;41(3):455-460.
- 803 13. Nezu T, Koga M, Nakagawara J, et al. Early ischemic change on CT versus diffusion-weighted imaging for
804 patients with stroke receiving intravenous recombinant tissue-type plasminogen activator therapy: stroke
805 acute management with urgent risk-factor assessment and improvement (SAMURAI) rt-PA registry. *Stroke*.
806 2011;42(8):2196-2200.
- 807 14. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with acute
808 ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American
809 Stroke Association. *Stroke*. 2013;44(3):870-947.
- 810 15. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and
811 transient ischemic attack: a guideline for healthcare professionals from the American Heart
812 Association/American Stroke Association. *Stroke*. 2014;45(7):2160-2236.
- 813 16. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific
814 statement for healthcare professionals from the American Heart Association/American Stroke Association
815 Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology
816 and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral

NOT FOR PUBLICATION, QUOTATION, OR CITATION

- 817 Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational
818 tool for neurologists. *Stroke*. 2009;40(6):2276-2293.
- 819 17. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for
820 healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*.
821 2013;44(7):2064-2089.
- 822 18. Jayaraman MV, Hussain MS, Abruzzo T, et al. Embolectomy for stroke with emergent large vessel occlusion
823 (ELVO): report of the Standards and Guidelines Committee of the Society of NeuroInterventional Surgery.
824 *Journal of neurointerventional surgery*. 2015;7(5):316-321.
- 825 19. Lyden P. Using the National Institutes of Health Stroke Scale: A Cautionary Tale. *Stroke*. 2017;48(2):513-
826 519.
- 827 20. Goyal N, Tsivgoulis G, Frei D, et al. A multicenter study of the safety and effectiveness of mechanical
828 thrombectomy for patients with acute ischemic stroke not meeting top-tier evidence criteria. *Journal of*
829 *neurointerventional surgery*. 2017.
- 830 21. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA
831 alone for stroke. *The New England journal of medicine*. 2013;368(10):893-903.
- 832 22. Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic
833 stroke. *The New England journal of medicine*. 2013;368(10):914-923.
- 834 23. Haussen DC, Bousslama M, Grossberg JA, et al. Too good to intervene? Thrombectomy for large vessel
835 occlusion strokes with minimal symptoms: an intention-to-treat analysis. *Journal of neurointerventional*
836 *surgery*. 2016.
- 837 24. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke:
838 a meta-analysis of individual patient data from five randomised trials. *Lancet*. 2016;387(10029):1723-1731.
- 839 25. Lemmens R, Hamilton SA, Liebeskind DS, et al. Effect of endovascular reperfusion in relation to site of
840 arterial occlusion. *Neurology*. 2016;86(8):762-770.
- 841 26. Coutinho JM, Liebeskind DS, Slater LA, et al. Mechanical Thrombectomy for Isolated M2 Occlusions: A
842 Post Hoc Analysis of the STAR, SWIFT, and SWIFT PRIME Studies. *AJNR. American journal of*
843 *neuroradiology*. 2016;37(4):667-672.
- 844 27. Sarraj A, Sangha N, Hussain MS, et al. Endovascular Therapy for Acute Ischemic Stroke With Occlusion of
845 the Middle Cerebral Artery M2 Segment. *JAMA neurology*. 2016;73(11):1291-1296.
- 846 28. Sheth SA, Yoo B, Saver JL, et al. M2 occlusions as targets for endovascular therapy: comprehensive analysis
847 of diffusion/perfusion MRI, angiography, and clinical outcomes. *Journal of neurointerventional surgery*.
848 2015;7(7):478-483.
- 849 29. Tomsick TA, Carrozzella J, Foster L, et al. Endovascular Therapy of M2 Occlusion in IMS III: Role of M2
850 Segment Definition and Location on Clinical and Revascularization Outcomes. *AJNR. American journal of*
851 *neuroradiology*. 2017;38(1):84-89.
- 852 30. Saver JL, Goyal M, van der Lugt A, et al. Time to Treatment With Endovascular Thrombectomy and
853 Outcomes From Ischemic Stroke: A Meta-analysis. *Jama*. 2016;316(12):1279-1288.
- 854 31. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT
855 II study: a randomized controlled trial. *Prolyse in Acute Cerebral Thromboembolism. Jama*.
856 1999;282(21):2003-2011.
- 857 32. Aghaebrahim A, Leiva-Salinas C, Jadhav AP, et al. Outcomes after endovascular treatment for anterior
858 circulation stroke presenting as wake-up strokes are not different than those with witnessed onset beyond 8
859 hours. *Journal of neurointerventional surgery*. 2015;7(12):875-880.
- 860 33. Noorian AR, Rangaraju S, Sun CH, et al. Endovascular Therapy in Strokes with ASPECTS 5-7 May Result in
861 Smaller Infarcts and Better Outcomes as Compared to Medical Treatment Alone. *Interventional neurology*.
862 2015;4(1-2):30-37.
- 863 34. Rebello LC, Bousslama M, Haussen DC, et al. Endovascular Treatment for Patients With Acute Stroke Who
864 Have a Large Ischemic Core and Large Mismatch Imaging Profile. *JAMA neurology*. 2017;74(1):34-40.

NOT FOR PUBLICATION, QUOTATION, OR CITATION

- 865 35. Yoo AJ, Berkhemer OA, Fransen PSS, et al. Effect of baseline Alberta Stroke Program Early CT Score on
866 safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR
867 CLEAN). *The Lancet. Neurology*. 2016;15(7):685-694.
- 868 36. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in
869 stroke. *The New England journal of medicine*. 2015;372(24):2285-2295.
- 870 37. Madaelil TP, Kansagra AP, Cross DT, Moran CJ, Derdeyn CP. Mechanical thrombectomy in pediatric acute
871 ischemic stroke: Clinical outcomes and literature review. *Interventional neuroradiology : journal of*
872 *peritherapeutic neuroradiology, surgical procedures and related neurosciences*. 2016;22(4):426-431.
- 873 38. American College of Radiology. ACR–SPR practice parameter for imaging pregnant or potentially pregnant
874 adolescents and women with ionizing radiation. 2013; Available at:
875 <https://www.acr.org/~media/9E2ED55531FC4B4FA53EF3B6D3B25DF8.pdf>. Accessed April 19, 2017.
- 876 39. American College of Radiology. ACR–ASNR–SIR–SNIS practice parameter for the performance of
877 diagnostic cervicocerebral catheter angiography in adults. 2016; Available at:
878 <https://www.acr.org/~media/261A171F55D744439FAACD9C61B0D462.pdf>. Accessed June 2, 2017.
- 879 40. Powers WJ, Derdeyn CP, Biller J, et al. 2015 American Heart Association/American Stroke Association
880 Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke
881 Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart
882 Association/American Stroke Association. *Stroke*. 2015;46(10):3020-3035.
- 883 41. Sacks D, Black CM, Cognard C, et al. Multisociety consensus quality improvement guidelines for intraarterial
884 catheter-directed treatment of acute ischemic stroke, from the American Society of Neuroradiology, Canadian
885 Interventional Radiology Association, Cardiovascular and Interventional Radiological Society of Europe,
886 Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of
887 NeuroInterventional Surgery, European Society of Minimally Invasive Neurological Therapy, and Society of
888 Vascular and Interventional Neurology. *Journal of vascular and interventional radiology : JVIR*.
889 2013;24(2):151-163.
- 890 42. Training Guidelines for Endovascular Ischemic Stroke Intervention: An International multi-society consensus
891 document. *Journal of neurointerventional surgery*. 2016;8(10):989-991.
- 892 43. American College of Radiology. ACR practice parameter for continuing medical education (CME). 2016;
893 Available at: <https://www.acr.org/~media/FBCDC94E0E25448DAD5EE9147370A8D1.pdf>. Accessed April
894 19, 2017.
- 895 44. American College of Radiology. ACR–SIR practice parameter for sedation/analgesia. 2015; Available at:
896 <https://www.acr.org/~media/F194CBB800AB43048B997A75938AB482.pdf>. Accessed April 19, 2017.
- 897 45. Ang TE, Bivard A, Levi C, et al. Multi-modal CT in acute stroke: wait for a serum creatinine before giving
898 intravenous contrast? No! *International journal of stroke : official journal of the International Stroke Society*.
899 2015;10(7):1014-1017.
- 900 46. American College of Radiology. ACR–SIR–SPR practice parameter on informed consent for image-guided
901 procedures. 2016; Available at: <https://www.acr.org/~media/1A03224CA4894854800C516012B6DB5A.pdf>.
902 Accessed May 31, 2017.
- 903 47. Talke PO, Sharma D, Heyer EJ, Bergese SD, Blackham KA, Stevens RD. Society for Neuroscience in
904 Anesthesiology and Critical Care Expert consensus statement: anesthetic management of endovascular
905 treatment for acute ischemic stroke*: endorsed by the Society of NeuroInterventional Surgery and the
906 Neurocritical Care Society. *Journal of neurosurgical anesthesiology*. 2014;26(2):95-108.
- 907 48. Butcher K, Christensen S, Parsons M, et al. Postthrombolysis blood pressure elevation is associated with
908 hemorrhagic transformation. *Stroke*. 2010;41(1):72-77.
- 909 49. Oliveira-Filho J, Silva SC, Trabuco CC, Pedreira BB, Sousa EU, Bacellar A. Detrimental effect of blood
910 pressure reduction in the first 24 hours of acute stroke onset. *Neurology*. 2003;61(8):1047-1051.

NOT FOR PUBLICATION, QUOTATION, OR CITATION

- 911 50. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe
 912 Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. *Lancet*.
 913 2007;369(9558):275-282.
- 914 51. Mandzia JL, Hill MD. Acute stroke management in patients with known or suspected atrial fibrillation. *The*
 915 *Canadian journal of cardiology*. 2013;29(7 Suppl):S45-53.
- 916 52. Fuentes B, Castillo J, San Jose B, et al. The prognostic value of capillary glucose levels in acute stroke: the
 917 GLyemia in Acute Stroke (GLIAS) study. *Stroke*. 2009;40(2):562-568.
- 918 53. De Georgia M, Patel V. Critical care management in acute ischemic stroke. *Journal of neurointerventional*
 919 *surgery*. 2011;3(1):34-37.
- 920 54. Kramer AH, Zygun DA. Anemia and red blood cell transfusion in neurocritical care. *Crit Care*.
 921 2009;13(3):R89.
- 922 55. American College of Radiology. ACR–SIR–SPR practice parameter for the reporting and archiving of
 923 interventional radiology procedures. 2014; Available at:
 924 <https://www.acr.org/~media/B6AD9A7E4D5E411DA9C3E19E86F9311F.pdf>. Accessed April 19, 2017.
- 925 56. modified Rankin Scale (mRS). Available at: <http://www.rankinscale.org/>. Accessed July 3, 2017.
- 926 57. National Institutes of Health. NIH Stroke Scale. Available at: <http://www.nihstrokescale.org/>. Accessed July
 927 3, 2017.
- 928 58. Zaidat OO, Yoo AJ, Khatri P, et al. Recommendations on angiographic revascularization grading standards
 929 for acute ischemic stroke: a consensus statement. *Stroke*. 2013;44(9):2650-2663.

Appendix A

**Society of Interventional Radiology
 Standards of Practice Committee
 Classification of Complications by Outcome**

Minor Complications

- 937 A. No therapy, no consequence
 938 B. Nominal therapy, no consequence; includes overnight admission for observation only

Major Complications

- 941 C. Require therapy, minor hospitalization (<48 hours)
 942 D. Require major therapy, unplanned increase in level of care, prolonged hospitalization (>48 hours)
 943 E. Permanent adverse sequelae
 944 F. Death

Appendix B**modified Rankin Scale [56]**

- 950 0 = Grade 0: No signs or symptoms
 951 1 = Grade 1: No significant disability; able to carry out all the usual activities of daily living without assistance.
 952 NOTE: This does not preclude the presence of weakness, sensory loss, language disturbance, etc, but implies
 953 that these are mild and do not or have not caused patient to limit his/her activities (eg, if employed before, is
 954 still employed at the same job).
- 955 2 = Grade 2: Slight disability; unable to carry out some previous activities but able to look after own affairs
 956 without much assistance (eg, unable to return to prior job, unable to do some household chores, but able to get
 957 along without daily supervision or help)
- 958 3 = Grade 3: Moderate disability requiring some help but able to walk without assistance (eg, needs daily
 959 supervision; needs assistance with small aspects of dressing, hygiene; unable to read or communicate clearly).
 960 NOTE: Use of ankle-foot orthotic or cane does not imply that the patient needs assistance.

NOT FOR PUBLICATION, QUOTATION, OR CITATION

- 961 4 = Grade 4: Moderately severe disability; unable to walk without assistance and unable to attend bodily needs
- 962 without assistance (eg, needs 24-hour supervision and moderate to maximum assistance on several activities
- 963 of daily living but still able to do some activities by self or with minimal assistance)
- 964 5 = Grade 5: Severe disability; bedridden, incontinent, and requiring constant nursing care and attention
- 965 6 = Stroke death
- 966 9 = Unknown (not obtainable from history or no follow-up)
- 967

NOT FOR PUBLICATION, QUOTATION, OR CITATION

968
969
970

Appendix C

National Institutes of Health Stroke Scale Worksheet for Scoring Stroke Symptoms [57]

STROKE CENTER STROKE SCALE FLOWSHEET
National Institute of Health Stroke Scale (NIHSS)

A complete NIH Stroke score consists of all 11 elements of the NIH Stroke Scale. A modified NIH Stroke scale consists of asterisk (*) items 1, 4, 5, 6. Pupil exam may be ordered in addition to the NIH Stroke scale, but is not included in the score. GCS is NOT included on the flowsheet, but ordered separately.		Enter Stroke Scale scores for each item in the space provided. NT denotes non-testable.	DATE					
			TIME					
LEVEL OF CONSCIOUSNESS	*1a. Level of consciousness	0 = alert 1 = drowsy but arousable 2 = stuporous 3 = coma						
	*1b. Level of consciousness questions (month, age)	0 = answers both correctly 1 = answers one correctly 2 = both incorrect						
	*1c. Level of consciousness commands (1. open, then close eyes 2. make fist, then let go)	0 = performs both correctly 1 = performs one correctly 2 = both incorrect						
VISION	2. Best gaze (ability to follow examiner's finger across horizontal plane)	0 = normal 1 = partial gaze palsy 2 = forced deviation						
	3. Visual (visual stimulus to patient's visual field quadrants - see diagram on back of form)	0 = no visual loss 1 = partial hemianopsia 2 = complete hemianopsia 3 = bilateral hemianopsia (blind)						
MOVEMENT	*4. Facial palsy (shows teeth, raise eyebrows, squeeze eyes shut)	0 = normal 1 = minor asymmetry upon smiling, flattened nasolabial fold 2 = partial (total or near total paralysis of lower face) 3 = complete absence of movement in upper and lower face (of one or both sides)						
	*5a. Motor arm - LEFT	0 = no drift for 10 seconds 1 = drift, does NOT hit bed 2 = some effort against gravity, limb falls to bed, some movement 3 = no effort against gravity, limb falls to bed, some movement 4 = no movement NT = amputation, joint fusion (explain)	Left					
	*5b. Motor arm - RIGHT (extends arms with palms DOWN to 90 degrees if sitting, 45 degrees if supine and hold for 10 seconds - score drift/movement)		Right					
	*6a. Motor leg - LEFT	0 = no drift for 5 seconds 1 = drift, does NOT hit bed 2 = some effort against gravity, limb falls to bed, some movement 3 = no effort against gravity, limb falls to bed, some movement 4 = no movement NT = amputation, joint fusion (explain)	Left					
	*6b. Motor leg - RIGHT (while supine, hold leg at 30 degrees for 5 seconds - score drift/movement)		Right					
	7. Limb ataxia (finger to nose, heel down shin)	0 = absent or affected limb too weak to perform exam 1 = present in one limb 2 = present in two limbs						
SENSORY	8. Sensory (pin prick to face, arm, trunk and leg - compare side to side)	0 = normal 1 = mild to moderate loss "not as sharp" 2 = severe loss, total sensory loss, patient unaware of being touched						
LANGUAGE	9. Best language (name items, describe a picture and read sentences - see reverse side for use of words and pictures to aide in assessment)	0 = no aphasia 1 = mild to moderate aphasia, examiner can identify picture from patient response 2 = severe aphasia, examiner CANNOT identify pictures from patient response 3 = mute, no useable speech						
	10. Dysarthria (evaluate speech clarity by patient repeating listed words- see reverse side for use of words to aide in assessment)	0 = normal 1 = mild, slurs some words 2 = severe, slurred speech, unintelligible or mute NT = intubated or other physical barrier (explain)						
	11. Extinction and inattention (use information from prior testing to identify neglect or double simultaneous stimuli testing - modality: visual, tactile/auditory, spacial)	0 = normal 1 = inattention or extinction in one modality 2 = profound hemi-inattention or hemi-inattention in more than one modality						
EYES	Pupil exam (see reverse side for diagram of mm) Not included in NIHSS Stroke Scale score Reactive = R Nonreactive = N		Size	Left				
			Reaction	Left				
Initials/Signatures:			Size	Right				
			Reaction	Right				
			Total MODIFIED NIH Stroke Scale Score:					
			Total COMPLETE NIH Stroke Scale Score:					
			Initials:					

Patient Name

STROKE CENTER STROKE SCALE FLOWSHEET

971
972

NOT FOR PUBLICATION, QUOTATION, OR CITATION973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994**Appendix D****Modified Thrombolysis in Cerebral Ischemia (mTICI) Scale [58]****Grade Definitions**

- | | |
|----|---|
| 0 | No perfusion |
| 1 | Antegrade reperfusion past the initial occlusion, but limited distal branch filling with little or slow distal reperfusion |
| 2a | Antegrade reperfusion of less than half of the occluded target artery previously ischemic territory |
| 2b | Antegrade reperfusion of more than half of the previously occluded target artery ischemic territory |
| 3 | Complete antegrade reperfusion of the previously occluded target artery ischemic territory, with absence of visualized occlusion in all distal branches |

*Practice parameters and technical standards are published annually with an effective date of October 1 in the year in which amended, revised or approved by the ACR Council. For practice parameters and technical standards published before 1999, the effective date was January 1 following the year in which the practice parameter or technical standard was amended, revised, or approved by the ACR Council.

Development Chronology for This Practice Parameter